Navigation Links
Novelos Therapeutics Prices $5.5 Million Public Offering
Date:2/13/2013

ACTS
J. Patrick Genn , Vice President of IR, Novelos Therapeutics, Inc., Madison, Wisc. & Boston, Mass., Ph: (858) 775-7456, Email: jpgenn@novelos.com

Anne Marie Fields , Senior Vice President, LHA, Ph: (212) 838-3777, Email: afields@lhai.com, @LHA_IR_PR

This news release contains forward-looking statements.  You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates.  Such statements are valid only as of today, and we disclaim any obligation to update this information.  These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Drug discovery and development involve a high degree of risk.  Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our  pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.


'/>"/>
SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Novelos Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference On February 11
2. Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
3. Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29
4. Novelos Therapeutics Closes $2 Million Private Placement
5. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
6. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
7. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
8. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
9. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
10. Novelos Therapeutics Prices $5.4 Million Public Offering
11. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... -- bioMérieux, a world leader in the field of ... the White House Forum on Antibiotic Stewardship for the ... means to address antibiotic resistance. Over 150 major experts ... to discuss the possible ways to implement changes over ... antibiotic-resistant bacteria, and prevent the spread of resistant infections ...
(Date:6/1/2015)... , June 1, 2015 Nevro Corp. ... that is providing innovative evidence-based solutions for the treatment ... an underwritten public offering of its common stock consisting ... 2,459,175 shares to be sold by certain of its ... a 30-day option to purchase up to an additional ...
(Date:6/1/2015)... Select Medical Holdings Corporation (NYSE: SEM ... venture that Select Medical Corporation ("Select") formed with Welsh, ... announced acquisition of Concentra Inc.  Cressey & Company has ... About Select Medical Corporation Select ... rehabilitation clinics in the United States ...
Breaking Medicine Technology:bioMerieux Honored to Participate in the White House Forum on Antibiotic Stewardship 2bioMerieux Honored to Participate in the White House Forum on Antibiotic Stewardship 3Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 2Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 3
... oncology electronic medical record (EMR) has ... validates the Elekta software and enables eligible providers ... under the HITECH Act.   Tested ... Records Office of the National Coordinator Authorized Testing ...
... ERT (Nasdaq: ERES ), announced today that ... Keith Schneck, the Company,s Chief Financial Officer, are scheduled ... Conference at 10:00 AM ET on March 2, 2011 in ... the presentation by visiting the Company,s corporate website at  ...
Cached Medicine Technology:Elekta's Oncology-Specific MOSAIQ Receives Complete ONC-ATCB EMR Certification 2Elekta's Oncology-Specific MOSAIQ Receives Complete ONC-ATCB EMR Certification 3ERT to Present at the Citi 2011 Global Health Care Conference on March 2, 2011 2
(Date:6/2/2015)... Mercy Health (formerly Catholic Health Partners) ... – has devoted the seventh of its monthly Mercy ... prevention. One in five Americans will get skin cancer. ... channel, a Mercy Health expert addresses these skin cancer-related ... of skin cancer? ,     What are the main ...
(Date:6/2/2015)... The Radiosurgery Society® (RSS), a non-profit ... Patient Registry evaluating the treatment patterns and clinical ... treatment of centrally located primary non-small cell lung ... study, published in the May, 2015, issue of ... with 114 centrally located lung tumors who were ...
(Date:6/2/2015)... Dallas, TX (PRWEB) June 02, 2015 FDA ... to qualified Diet Doc patients after a satisfactory doctor consultation. ... on the market for several years and has the longest ... Working to block the enzyme that breaks down fats in ... diverting them through the intestinal system to be excreted through ...
(Date:6/2/2015)... 2015 Thermi, formerly ThermiAesthetics, a ... successfully transitioned into its new company headquarters in ... company’s continued rapid worldwide expansion and houses the ... 25 Thermi employees, including those of the warehousing, ... “As one of the fastest growing aesthetic companies ...
(Date:6/2/2015)... June 02, 2015 While the movie ... of comic books, comic books themselves are stepping into ... Uniting Nations plans to produce educational comics in multiple ... Goals for Sustainable Development - an international effort to ... hunger, health, education, sustainable energy, inequality, climate change and ...
Breaking Medicine News(10 mins):Health News:Video provides helpful information about skin cancer prevention 2Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 2Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 3Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 2Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 3Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 4Health News:Thermi Moves to New Corporate Headquarters as Rapid Company Expansion Continues 2Health News:Can Comics Help the United Nations Save the World? 2Health News:Can Comics Help the United Nations Save the World? 3
... High alkaline phosphatase levels boosted mortality 25% in chronic ... High levels of alkaline phosphatase -- a routinely measured ... risk of death among patients receiving dialysis for chronic ... data on almost 74,000 hemodialysis patients during a three-year ...
... researchers say , , THURSDAY, July 31 (HealthDay News) -- ... mechanisms behind a problem that has bedeviled many men, ... , The study identifies a key signaling molecule that ... "These are very complex molecular signals, and the authors ...
... PITTSBURGH, July 31 Mylan Inc. (NYSE: MYL ... preferred stock,issuance, the company has declared its quarterly dividend ... of 6.5% and a liquidation,preference of $1,000.00 per share) ... of record as of August 1, 2008., Mylan ...
... ATRC ), a medical device company and a leader in ... following,investor conferences during August:, -- The BMO Focus on ... the Millennium Broadway Hotel in New York. David J. Drachman, President ... present at 9:00 a.m. Eastern time., ...
... to permit the State of Michigan to spray the ... of this important antibiotic to treat blood infections in ... Infectious Diseases Society of America (IDSA). , The ... of Michigan "emergency" permission to use gentamicin to fight ...
... Mich. Pat Phalin learned she had hearing loss at ... local school. The pupils heard sounds she could not hear. ... pattern in his wife,s family history. Her mother, grandfather and ... Phalins, children had hearing problems before he reached school age. ...
Cached Medicine News:Health News:Bone Disease Test Shows Death Risk for Dialysis Patients 2Health News:Mouse Study Finds Molecule That Tells Hair to Grow 2Health News:AtriCure to Present at the BMO Focus on Healthcare and Canaccord Adams Global Growth Conferences in August 2Health News:Physicians ask EPA, 'Antibiotics to cure sick apples, or sick children?' 2Health News:Inherited form of hearing loss stems from gene mutation 2Health News:Inherited form of hearing loss stems from gene mutation 3
Inquire...
...
Liquichek Elevated CRP Control is a liquid assayed serum control with elevated levels of C-Reactive Protein....
LiquichekCardiac Markers Plus Control LT is a premium, comprehensive cardiac assessment control with many analytes and long stability....
Medicine Products: